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EFFECT OF BODY COMPOSITION AND RENAL FUNCTION ON THE PHAR-
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nia, Philadelphia; 2University of Pennsylvania, Philadelphia; 3University
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Background:High dosemelphalan is themost common regimen for
autologous stem cell transplantation (ASCT) for multiple myeloma
(MM), but toxicity and efficacy are variable. We hypothesized that
variation in body size, body composition, and renal function would
explain differences in melphalan pharmacokinetics and therefore in
outcomes after transplant.
Methods: We evaluated 41 patients who received melphalan 200
mg/m2 on day -2 (one patient with poor renal function received
180mg/m2).We calculatedmelphalan doses using ideal body weight
(IBW), using adjusted IBW (ABW) for patients weighing.120% of
IBW.Wemeasured body composition using dual x-ray absorptiom-
etry (DEXA), renal function with both iohexol clearance (Cliohexol)
and the Cockroft-Gault formula (CrClCG), and plasma melphalan
concentrations using HPLC/tandem mass spectrometry. We used
non-compartmental analysis to estimate melphalan clearance
(ClMEL) and area under the curve (AUCMEL) and linear regression
modeling to identify factors associated with melphalan pharmacoki-
netics.
Results: Patients’ mean BSA using actual weight was 1.93 m2 (range
1.44-2.48). By DEXA scan, the mean lean body weight was 53.3 kg
(SD 11.0) and mean fat percentage 31% (SD 9.5%). Mean iohexol
clearance was 109 mL/min (range 28-163). AUCMEL varied signifi-
cantly, with a range of 7.6-26.6 mg*h/L (mean 13.6, SD 3.8); ClMEL
was similarly variable (mean 27.9mL/min, SD 8.1). In univariate anal-
yses, ClMEL was inversely related to age and directly related to weight,
BSA, lean body weight, bone mineral content, Cliohexol, CrClCG, and
MEL dose. ClMEL was not associated with body fat percentage,
body fat weight, or body lean percentage, or with othermeasurements,
such as hemoglobin, albumin, immunoglobulins, or M-spike. The
strongest correlation with ClMEL was for CrClCG, and multivariable
models showed no improved prediction of ClMEL with the addition
of other factors to CrClCG. The best model for predicting AUCMEL
was dose/CrClCG (see table). These models consistently under-pre-
dicted AUCMEL (mean prediction error -3.3% to -2.6%).
Table. Performance of linear models predicting AUCMEL
Model R2 p-valuedose/CrClCG 0.26 0.001
dose/Cliohexol 0.11 0.04
dose/weight 0.10 0.04
dose/lean weight 0.08 0.08
dose/BSAIBW 0.06 0.11
dose/BSAABW 0.04 0.23Conclusion:A composite calculation incorporating age, weight, and
serum creatinine, like CrClCG, may be the best way to choose mel-
phalan doses but only explains 26% of drug exposure variability.
Other measures of body composition were poor predictors of expo-
sure. Further research is needed to better address the remaining var-
iability in drug clearance and exposure.120
COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF
VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION
REGIMENS IN MULTIPLE MYELOMA PATIENTS
Tuffaha, H.W.1, Hussein, A.A.2, Abdel-Rahman, F.A.2 1King Hussein
Cancer Center, Amman, Jordan; 2King Hussein Cancer Center, Amman,
Jordan
Introduction: Plerixafor is a novel agent that enhances the mobili-
zation of peripheral blood stem cells (PBSCs) in lymphoma andmul-tiple myeloma (MM) patients whose cells mobilize poorly. Due to
the substantial cost associated with its use, a cost utility analysis
was performed to evaluate the economics of salvage Plerixafor in
MM patients who failed previous mobilization.
Methods: A decisionmodel was developed to analyze the cost utility
for two salvage regimens: Plerixafor + GCSF (PG) versus Cyclo-
phosphamide + GCSF (CG). The model assumes that patients un-
dergo mobilization with one of the regimens, followed by
apheresis and subsequent autologous transplant if CD34+ cell count
is $ 2 x 106 cells/kg, or Bortezomib plus Dexamethasone if insuffi-
cient CD34+ cells are collected. Patients included in the model
will eventually progress and die from their disease. A structured lit-
erature review was performed to collect data on the successful mobi-
lization rate, life year gained and quality of life associated with the
modeled options. The analysis was from the perspective of Jordanian
Ministry of Health; the costs were based on its list prices and in-
cluded the costs of medications, apheresis, autologous transplant
and adverse effects management. The willingness to pay threshold
was $30,000 per quality adjusted life year (QALY). Incremental
cost effectiveness ratio (ICER) was calculated by dividing the incre-
mental average cost by the incremental QALY gained. One-way sen-
sitivity analysis was performed to explore the impact of the
uncertainty in efficacy data on the results.
Results: The model showed that PG was associated with higher
probability of achieving successful re-mobilization and subsequent
transplant. The average total costs associated with CG and PG
were $41,500 and $58,400 respectively. The estimated ICER was
$52,813/QALY. (Table 1) The sensitivity analysis revealed that the
ICERs ranged from $86,500 to $40,488 per QALY gained when the
probability of PG success ranged from 60% to 95%.
Conclusion: This analysis showed that the use of Plerixafor plus
GCSF as salvage mobilization regimen in MM patients was not
cost effective compared to Cyclophosphamide plus GCSF from
the perspective of our health care system. To our knowledge, this
is the first study to describe a cost utility analysis of Plerixafor use
in this indication.
Table 1. Analysis of Plerixafor plus GCSF (PG) versus Cyclo-
phosphamide plus GCSF (CG)
Incremental
Regimen PG CG resultsProbability of successful
mobilization0.80 0.27 0.53Average total costs $58,400 $41,500 $16,900
Life year gained 4.3 3.8 0.50
QALY 2.58 2.26 0.32
ICER ($/QALY gained)
for PG
$52,813121
OUTCOME OF PATIENTS WITH NONSECRETORY MULTIPLE MYELOMA
AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Farhan, S., Lin, H., Baladandayuthapani, V., Shah, N., Bashir, Q.,
Hosing, C., Popat, U., Parmar, S., Dinh, Y., Qureshi, S., Rondon, G.,
Giralt, S., Champlin, R., Qazilbash, M. The University of Texas MD
Anderson Cancer Center, Houston, TX
Background: More than 95% of patients with multiple myeloma
have a detectable monoclonal protein either in the serum or urine.
Less than 5% of patients have non-secertory myeloma (NSM), char-
acterized by the absence of a monoclonal protein. There are limited
available data on the outcome of patients withNSM (Ref. Kumar S et
al.). We studied the outcomes of patients with NSM after high-dose
chemotherapy and autologous hematopoietic stem cell transplanta-
tion (auto-HCT), and compared them to a matched group of pa-
tients with secretory myeloma (SM).
Methods: Between 1988 and December 2010, 1567 patients with
MMreceived auto-HCTat our institution.We identified 31 patients
with NSM and compared their outcome to a matched group of 94
patients with SM. Patients were matched for age at auto-HCT,
Durie-Salmon stage, response to therapy prior to auto-HCT, and
the year of auto-HCT. Variables for the two groups were compared
using the conditional logistic regression method to adjust the
